Safeguarding injured Victorians: development and implementation of an evidence-informed system to manage therapeutic uncertainty and decision making in a compensable environment
Lisa J. Sherry A D , Andrew M. Briggs
A B and Tania Pizzari A C
A Health Strategy, WorkSafe Victoria, Level 9, 567 Collins Street, Melbourne, Vic. 3000, Australia. Email: Lisa_sherry@worksafe.vic.gov.au
B Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, WA 6845, Australia. Email: A.Briggs@curtin.edu.au
C La Trobe Sports and Exercise Medicine Research Centre, La Trobe University, Bundoora, Vic. 3086, Australia. Email: T.Pizzari@latrobe.edu.au
D Corresponding author. Email: Lisa_Sherry@worksafe.vic.gov.au
Australian Health Review 44(3) 493-496 https://doi.org/10.1071/AH19155
Submitted: 2 July 2019 Accepted: 29 July 2019 Published: 26 November 2019
Journal Compilation © AHHA 2020 Open Access CC BY-NC-ND
Abstract
WorkSafe Victoria and the Transport Accident Commission are two Victorian government agencies that determine the policies that guide decisions to fund treatments and services provided to Victorians injured in transport or workplace accidents. These agencies identified that an internal system was required to manage requests for funding of new or emerging treatments. In particular, the agencies recognised a system that supported consistency in decision making in the context of therapeutic uncertainty and ensured the safety of injured Victorians was needed. The New, Emerging or Non-Established Treatments (NENETs) policy was launched in its current form by the agencies in 2013. The NENETs system includes a record of contemporary evidence for emerging treatments and an evidence-informed decision-making system to ensure consistency and information sharing. A system of recording decisions on emerging treatments was also implemented to ensure that funding decisions could later be reversed if necessary. The NENETs system has proved to be a robust and sustainable method of managing uncertainty for WorkSafe Victoria and the Transport Accident Commission and could be transferable to other funding bodies.
What is known about the topic? An algorithm to guide clinicians when prescribing off-label medications was developed in 2006, although it has not been used widely in everyday practice. In 2019 the Medical Board of Australia launched a discussion paper on ‘complementary and unconventional medicine and emerging treatments’ because no system for managing such treatments exists. Third-party payers have a responsibility to make objective and reliable decisions about new, emerging or non-established treatments to ensure high value care is offered to health consumers.
What does this paper add? This paper provides an overview of the policy and decision-making system implemented by WorkSafe Victoria and the Transport Accident Commission to managing requests for new, emerging or non-established treatments. The system is adaptable to other third-party payers, health service funders and regulators in Australia and internationally.
What are the implications for practitioners? It is important that practitioners caring for injured Victorians are aware of the systems used to inform decision making around requests for funding new, emerging or non-established treatments. Knowledge of the principles underlying this system may assist other funding bodies and the Medical Board of Australia to develop systems in other jurisdictions.
References
[1] Access to Medicines Working Group (AMWG). Access to Medicines Working Group interim report to government, July 2008. Canberra: Department of Health; 2008. Available at: http://www.pbs.gov.au/info/general/working-groups/amwg/amwg-interim-report-2008 [verified 30 September 2019].[2] Kaye KI, Lu CY, Day RO. Can we deny patients expensive drugs? Aust Prescr 2006; 29 146–8.
| Can we deny patients expensive drugs?Crossref | GoogleScholarGoogle Scholar |
[3] Cheng AC, Robinson PM, Harvey K. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2007; 186 379–80.
| 17407439PubMed |
[4] WorkSafe Victoria. Non-established, new or emerging treatments and services policy. Geelong: WorkSafe Victoria; 2013. Available at: https://www.worksafe.vic.gov.au/non-established-new-or-emerging-treatments-and-services-policy [verified 5 February 2019].
[5] Transport Accident Commission. Non-established, new or emerging treatments and services (NeNETS) policy. Geelong: TAC; 2013. Available at: https://www.tac.vic.gov.au/clients/what-we-can-pay-for/policies/other/non-established,-new-or-experimental-treatment [verified 5 February 2019].
[6] Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury Publishing; 2007.
[7] O’Malley SP, Selby WS, Jordan E. A successful practical application of Coverage with Evidence Development in Australia: Medical Services Advisory Committee interim funding and the PillCam Capsule Endoscopy Register. Int J Technol Assess Health Care 2009; 25 290–6.
| A successful practical application of Coverage with Evidence Development in Australia: Medical Services Advisory Committee interim funding and the PillCam Capsule Endoscopy Register.Crossref | GoogleScholarGoogle Scholar | 19619347PubMed |
[8] Elshaug AG, Rosenthal MB, Lavis JN, Brownlee S, Schmidt H, Nagpal S, Littlejohns P, Srivastava D, Tunis S, Saini V. Levers for addressing medical underuse and overuse: achieving high-value health care. Lancet 2017; 390 191–202.
| Levers for addressing medical underuse and overuse: achieving high-value health care.Crossref | GoogleScholarGoogle Scholar | 28077228PubMed |
[9] Murgatroyd DF, Casey PP, Cameron ID, Harris IA. The effect of financial compensation on health outcomes following musculoskeletal injury: systematic review. PLoS One 2015; 10 e0117597
| The effect of financial compensation on health outcomes following musculoskeletal injury: systematic review.Crossref | GoogleScholarGoogle Scholar | 25680118PubMed |
[10] Donoghue E. Non-established, new or experimental treatments (NENET). Evidence summary. Melbourne: Transport Accident Commission; 2010.
[11] Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006; 185 544–8.
| 17115966PubMed |
[12] Canadian Agency for Drugs and Technologies in Health (CADTH). Viscosupplementation for osteoarthritis of the hip, ankle, or shoulder: clinical effectiveness. Ottawa: CADTH; 2010. Available at: https://www.cadth.ca/sites/default/files/pdf/20100503-141823_k0184_viscosupplementation_for_oa_final.pdf [verified 30 September 2019].
[13] Royal Australian College of General Practitioners (RACGP). Guideline for the management of knee and hip osteoarthritis. 2nd edn. Melbourne: RACGP; 2018. Available at: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/hip-and-knee-osteoarthritis [verified 30 September 2019].
[14] Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, Bundschu R, Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: the SENZA-RCT randomized controlled trial. Anesthesiology 2015; 123 851–60.
| Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: the SENZA-RCT randomized controlled trial.Crossref | GoogleScholarGoogle Scholar | 26218762PubMed |
[15] Medical Board of Australia (MBA). Public consultation on clearer regulation of medical practitioners who provide complementary and unconventional medicine and emerging treatments. Melbourne: MBA; 2019. Available at: https://www.medicalboard.gov.au/News/Past-Consultations/Consultations-February-2019.aspx [verified 30 September 2019].
